These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 31846530)

  • 1. Targeted therapies in gynaecological cancers.
    Crusz SM; Miller RE
    Histopathology; 2020 Jan; 76(1):157-170. PubMed ID: 31846530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted therapy for gynecologic cancers: Toward the era of precision medicine.
    Basu P; Mukhopadhyay A; Konishi I
    Int J Gynaecol Obstet; 2018 Oct; 143 Suppl 2():131-136. PubMed ID: 30306576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PARP inhibitors and immunotherapy in ovarian and endometrial cancers.
    Miller RE; Lewis AJ; Powell ME
    Br J Radiol; 2021 Dec; 94(1128):20210002. PubMed ID: 33882241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The NCI-MATCH trial and precision medicine in gynecologic cancers.
    Barroilhet L; Matulonis U
    Gynecol Oncol; 2018 Mar; 148(3):585-590. PubMed ID: 29366510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination Immune Checkpoint Blockade Strategies to Maximize Immune Response in Gynecological Cancers.
    Liu YL; Zamarin D
    Curr Oncol Rep; 2018 Nov; 20(12):94. PubMed ID: 30421009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endometrial cancer: Molecular markers and management of advanced stage disease.
    Arend RC; Jones BA; Martinez A; Goodfellow P
    Gynecol Oncol; 2018 Sep; 150(3):569-580. PubMed ID: 29843906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy: Checkpoint Inhibitors in Lynch-Associated Gynecologic Cancers.
    Ferriss JS; Williams-Brown MY
    Curr Treat Options Oncol; 2019 Aug; 20(10):75. PubMed ID: 31444655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular and Genomic Determinants of Response to Immune Checkpoint Inhibition in Cancer.
    Jenkins RW; Thummalapalli R; Carter J; Cañadas I; Barbie DA
    Annu Rev Med; 2018 Jan; 69():333-347. PubMed ID: 29099676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting Programmed Cell Death -1 (PD-1) and Ligand (PD-L1): A new era in cancer active immunotherapy.
    Constantinidou A; Alifieris C; Trafalis DT
    Pharmacol Ther; 2019 Feb; 194():84-106. PubMed ID: 30268773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current Possibilities of Gynecologic Cancer Treatment with the Use of Immune Checkpoint Inhibitors.
    Grywalska E; Sobstyl M; Putowski L; Roliński J
    Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31547532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current Systemic Treatment Landscape of Advanced Gynecologic Malignancies.
    Pan K; Gong J; Huynh K; Cristea M
    Target Oncol; 2019 Jun; 14(3):269-283. PubMed ID: 31069647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Wnt signalling in gynaecological cancers: A future target for personalised medicine?
    Ford CE; Henry C; Llamosas E; Djordjevic A; Hacker N
    Gynecol Oncol; 2016 Feb; 140(2):345-51. PubMed ID: 26432042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endometrial cancer-targeted therapies myth or reality? Review of current targeted treatments.
    Lheureux S; Oza AM
    Eur J Cancer; 2016 May; 59():99-108. PubMed ID: 27017291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of bevacizumab on tumour angiogenesis and in the management of gynaecological cancers: A review.
    Chellappan DK; Leng KH; Jia LJ; Aziz NABA; Hoong WC; Qian YC; Ling FY; Wei GS; Ying T; Chellian J; Gupta G; Dua K
    Biomed Pharmacother; 2018 Jun; 102():1127-1144. PubMed ID: 29710531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted Therapy and Immune Therapy for Small Cell Lung Cancer.
    Gadgeel SM
    Curr Treat Options Oncol; 2018 Sep; 19(11):53. PubMed ID: 30203184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current knowledge and open issues regarding bevacizumab in gynaecological neoplasms.
    Bellati F; Napoletano C; Gasparri ML; Ruscito I; Marchetti C; Pignata S; Tomao F; Benedetti Panici P; Nuti M
    Crit Rev Oncol Hematol; 2012 Jul; 83(1):35-46. PubMed ID: 22056314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted therapies in gynecologic cancers.
    Chon HS; Hu W; Kavanagh JJ
    Curr Cancer Drug Targets; 2006 Jun; 6(4):333-63. PubMed ID: 16848724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrating Precision Medicine into the Contemporary Management of Gynecologic Cancers.
    Wolford JE; Ferrigni E; Margul D; Herzog TJ
    Curr Oncol Rep; 2022 Jul; 24(7):889-904. PubMed ID: 35347591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted therapy of ovarian cancer including immune check point inhibitor.
    Kim JY; Cho CH; Song HS
    Korean J Intern Med; 2017 Sep; 32(5):798-804. PubMed ID: 28823141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.
    Nuhn P; De Bono JS; Fizazi K; Freedland SJ; Grilli M; Kantoff PW; Sonpavde G; Sternberg CN; Yegnasubramanian S; Antonarakis ES
    Eur Urol; 2019 Jan; 75(1):88-99. PubMed ID: 29673712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.